Cross-over Study to Investigate Retinal Function Following Administration of a Single Dose of AZD9056

• Status: Completed
• Trial end date: 2008-08-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of the study is to determine whether treatment with a single 800mg dose of AZD9056, a medication which has been developed as a possible treatment for Rheumatoid Arthritis, has an effect on the function of the retina

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca

Criteria

Inclusion Criteria:

• Volunteers must be able to undergo the Electroretinography assessments

• Volunteers must have an intra ocular pressure of less than 25mmHg and 6/6 vision

Exclusion Criteria:

• Volunteers must pass a test that assesses whether they are at risk of narrow angle glaucoma

• Volunteers must not a family history of colour blindness, they must also pass a colour blindness test

• Volunteers must not have a history or current neurological or opthalmological (eye) disease